BOULDER, Colo.--Xenometrix, a biotech firm here with proprietary gene expression profiling technology and genotoxicology technology, received a cash infusion that the company said it expects will meet its operating requirements for two months. The infusion is the result of a letter of intent regarding a license for recently announced European patents and a US application and patents in the field of probe arrays.
The patents and application broadly cover methods and kits for producing gene expression profiles by exposing cells to pharmaceutical compounds and other chemicals, and then determining levels of expression of multiple genes in the cells. The company said these methods can be used by pharmaceutical and biotechnology companies to test compounds for efficacy and safety.